Compounded Tirzepatide: What You Need to Know (2026 Guide)

What Is Compounded Tirzepatide?

Compounded tirzepatide is the dual GIP/GLP-1 receptor agonist peptide (the same active ingredient in Mounjaro and Zepbound) prepared by a compounding pharmacy rather than manufactured by Eli Lilly. It's typically supplied as lyophilized (freeze-dried) powder in vials that you reconstitute with bacteriostatic water before injection, or as a pre-mixed injectable solution.

Unlike semaglutide, which targets only the GLP-1 receptor, tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual mechanism is what sets it apart, and why clinical trials have shown greater weight loss with tirzepatide compared to GLP-1-only agonists. In the SURMOUNT-1 trial, participants on 15mg tirzepatide lost an average of 20.9% of their body weight over 72 weeks.

Compounding pharmacies began producing tirzepatide as demand surged following Mounjaro's FDA approval in 2022 and Zepbound's approval in 2023. Chronic shortages made brand-name tirzepatide difficult to obtain, and the $1,000+/month cost without insurance put it out of reach for many. The compounded market grew rapidly, and so did the legal battles surrounding it.

Compounded vs Brand-Name Tirzepatide: Key Differences

One notable development: Eli Lilly introduced Zepbound single-dose vials at approximately $399/month in late 2024, a direct response to the compounding market. These vials contain FDA-approved tirzepatide at specific doses (2.5mg and 5mg initially) and don't require reconstitution. This narrowed the cost gap between brand-name and compounded options, though compounded tirzepatide remains cheaper at higher doses.

Why People Choose Compounded Tirzepatide

Cost

Brand-name Mounjaro and Zepbound cost $1,000–$1,100 per month without insurance. Even with Lilly's Zepbound vials at ~$399/month, compounded tirzepatide at $150–$600/month remains the more affordable option for many, especially at higher doses where brand-name costs stay the same but compounded costs scale with the actual amount of peptide used.

Availability

Tirzepatide shortages were widespread from 2023 through late 2024. Even after the FDA declared the shortage resolved in October 2024, many pharmacies reported sporadic stock issues with specific dose strengths. Compounding pharmacies provided consistent access during this period, and continue to for patients in areas where brand-name supply remains inconsistent.

Custom Dosing Flexibility

Tirzepatide's standard titration has six dose levels (2.5mg to 15mg). With compounded vials, you can dose at any increment: 3mg, 6mg, 8mg, or any amount your provider prescribes. This is particularly valuable for microdosing tirzepatide protocols or for patients who need to titrate more slowly than the standard 4-week escalation allows.

Combination Formulations

Like compounded semaglutide, many pharmacies now offer tirzepatide in combination with cyanocobalamin (vitamin B12), NAD+, or other ingredients. These combination products became especially important after the shortage list removal, since they're not "essentially a copy" of Mounjaro or Zepbound, they may fall outside certain compounding restrictions.

FDA and Legal Status: The Tirzepatide Compounding Battle

The regulatory and legal situation around compounded tirzepatide is significantly more contentious than compounded semaglutide. Eli Lilly has taken an aggressive approach that Novo Nordisk largely didn't: filing lawsuits, lobbying the FDA, and launching competing products to undercut the compounding market.

Timeline of Key Events

503A vs 503B Pharmacies

The regulatory framework for compounding centers on two sections of the Federal Food, Drug, and Cosmetic Act:

• Section 503A pharmacies: Traditional state-licensed compounding pharmacies that compound per individual patient prescription. Primarily overseen by state pharmacy boards. Smaller-scale operations.
• Section 503B outsourcing facilities: FDA-registered facilities that can produce larger batches, are subject to FDA inspections, must follow current Good Manufacturing Practices (cGMP), and have adverse event reporting requirements.

The practical reality: compounded tirzepatide remains available from some sources, but the legal ground is less stable than it was during the shortage period. If you're currently using compounded tirzepatide, your access depends on your specific pharmacy's legal position, the formulation they offer, and whether they're operating under court protection or have pivoted to combination products.

How to Source Compounded Tirzepatide Safely

Where you source matters, arguably more for tirzepatide than semaglutide given the legal complexity. A legitimate pharmacy operating within the law produces a well-characterized product. A questionable supplier is an unknown risk.

What to Look For

• State license verification: Confirm the pharmacy is licensed in your state through your state board of pharmacy website
• 503B registration: If they claim 503B status, verify on the FDA's registered outsourcing facility list
• Third-party testing: Reputable pharmacies test each batch for potency, purity, sterility, and endotoxins, and provide certificates of analysis (COAs) on request
• Valid prescription: Any legitimate source requires a prescription from a licensed provider. No prescription = not legitimate
• Cold chain shipping: Injectable tirzepatide requires temperature-controlled shipping. Adequate ice packs, insulated packaging, and timely delivery are non-negotiable
• Clear labeling: Pharmacy name and address, compound name and concentration, beyond-use date, storage instructions, and lot number should all appear on the label
• Legal compliance: Given the active litigation, a reputable pharmacy should be transparent about their legal basis for compounding tirzepatide, whether that's a court order, combination formulation, or patient-specific medical need

Dosing Considerations for Compounded Tirzepatide

The standard tirzepatide titration protocol applies regardless of source. The tirzepatide dosing guide covers this in full detail, and you can download a printable tirzepatide dosage chart for quick reference. Here's the standard escalation:

Compounded Tirzepatide Concentrations

Compounded tirzepatide vials come in various concentrations, commonly 10mg, 30mg, or 60mg total peptide content per vial. The concentration after reconstitution depends on how much bacteriostatic water you add. For example:

• 30mg vial + 3mL BAC water = 10mg/mL concentration
• 60mg vial + 3mL BAC water = 20mg/mL concentration
• 60mg vial + 6mL BAC water = 10mg/mL concentration

Use the tirzepatide calculator to plan your schedule and visualize how your dose translates to blood levels over time.

Reconstitution Basics

If your compounded tirzepatide arrives as lyophilized powder, you'll need to reconstitute it before use. Our tirzepatide reconstitution guide covers this in full detail. Here's the essential process:

1. Gather supplies: Bacteriostatic water (BAC water), alcohol swabs, insulin syringes, and your tirzepatide vial
2. Clean the vial tops: Wipe both the tirzepatide vial and BAC water vial with alcohol swabs
3. Draw BAC water: Using a syringe, draw your chosen volume of bacteriostatic water
4. Inject slowly: Insert the needle into the tirzepatide vial and inject the BAC water slowly down the side of the vial. Don't spray directly onto the powder
5. Gently swirl: Roll the vial between your palms. Never shake; this can damage the peptide
6. Wait for full dissolution: The solution should be clear and colorless. If particles remain, continue gently swirling. Tirzepatide may take slightly longer to dissolve than semaglutide due to its larger molecular structure

Storage and Stability

Proper storage is critical for maintaining peptide integrity. Tirzepatide, like other peptide medications, degrades when exposed to heat, light, or repeated temperature fluctuations.

Before Reconstitution

• Lyophilized powder: Store refrigerated (2–8°C / 36–46°F). Most suppliers indicate stability of 12–24 months when stored properly
• Room temperature: Brief periods at room temperature during shipping are generally acceptable, but prolonged exposure above 25°C (77°F) degrades the peptide
• Protect from light: Keep in the original packaging or a dark container

After Reconstitution

• Refrigerate immediately: Store reconstituted vials at 2–8°C (36–46°F)
• Beyond-use date: Most compounding pharmacies assign a 28–30 day beyond-use date after reconstitution. Follow your specific pharmacy's labeling
• Never freeze: Freezing reconstituted tirzepatide can damage the peptide structure
• Inspect before each use: The solution should remain clear and colorless. Discard if you see cloudiness, particles, or discoloration

Safety Considerations

Compounded tirzepatide carries the same category of risks as compounded semaglutide, plus some considerations specific to tirzepatide's dual mechanism and the more contentious legal environment.

Known Safety Concerns

Dosing errors: Tirzepatide doses are larger than semaglutide doses (up to 15mg vs 2.4mg), which means compounded vials contain more peptide. A small measurement mistake on a high-concentration vial can deliver a substantially larger overdose. This is the most preventable risk with compounded tirzepatide.

Salt form differences: As with semaglutide, some compounders use tirzepatide sodium or tirzepatide acetate rather than the base form used in FDA-approved products. The FDA's position is that these salt forms "have not been shown to be safe and effective." Whether they are functionally equivalent hasn't been established through clinical testing.

Dual mechanism sensitivity: Tirzepatide's activation of both GIP and GLP-1 receptors can produce more pronounced gastrointestinal effects than GLP-1-only agonists, particularly nausea and decreased appetite. An accidental overdose with compounded tirzepatide may therefore produce more severe GI symptoms than an equivalent error with semaglutide.

Sterility and purity: The same standards apply as with any compounded injectable. A verified 503B outsourcing facility with FDA oversight provides more quality assurance than an unregistered source. Request certificates of analysis (COAs) and verify the pharmacy's credentials.

For a full overview of tirzepatide-related adverse effects, whether from brand-name or compounded sources, see our tirzepatide side effects guide.

Fraudulent Products

The FDA has identified fraudulent compounded GLP-1 products in the US market, and tirzepatide is no exception. Products have been found with labels from non-existent pharmacies, incorrect concentrations, or no active ingredient at all. The higher price point of tirzepatide (compared to semaglutide) makes it an attractive target for counterfeiters. Verify your pharmacy's credentials independently, not just through the label on the vial.